Cancer of Unknown Primary Site Recruiting Phase 2 Trials for Oteracil (DB03209)

IndicationStatusPhase
DBCOND0089665 (Cancer of Unknown Primary Site)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs